Omnicell reports Q1 adjusted EPS 55c, consensus 33c

Reports Q1 revenue $310M, consensus $304.06M. “We delivered a strong start to 2026, driven by solid execution and sustained demand for our points of care solutions,” said Randall Lipps, chairman, president, CEO, and founder of Omnicell (OMCL). “As care environments continue to become more complex, we see that health systems are prioritizing reliability, efficiency, and standardization in medication workflows. During the quarter, we continued to advance solutions designed to support health systems as they manage increasingly complex medication workflows, optimize the medication supply chain, and improve operational efficiency while enhancing both the caregiver and patient experience.”